Press Release: OncoResponse : OncoResponse Announces Phase 1 Results of the Clinical Trial of OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer
/PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today...
Read full article »
OncoResponse is a Washington-based biotechnology company that researches and develops immunotherapies for the treatment of cancer.
Read more